These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 5902417)

  • 1. Catechloamine excretion in manic-depressive and schizophrenic psychosis and its relationship to symptomatology.
    Sloane RB; Hughes W; Haust HL
    Can Psychiatr Assoc J; 1966 Feb; 11(1):6-19. PubMed ID: 5902417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Catecholamine metabolism in manic-depressive psychosis].
    Usherenko LS
    Fiziol Zh; 1970; 16(3):393-9. PubMed ID: 5509683
    [No Abstract]   [Full Text] [Related]  

  • 3. Carbohydrate metabolism in brain disease. V. Effect of epinephrine on intermediary carbohydrate metabolism in schizophrenic and manic-depressive psychoses.
    HENNEMAN DH; ALTSCHULE MD; GONCZ RM; DAVIS P
    AMA Arch Intern Med; 1955 Apr; 95(4):594-600. PubMed ID: 14360835
    [No Abstract]   [Full Text] [Related]  

  • 4. Critique of single amine theories: evidence of a cholinergic influence in the major mental illnesses.
    Davis JM
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():333-46. PubMed ID: 3830
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased noradrenaline levels in CSF and plasma of schizophrenic patients.
    Kemali D; Del Vecchio M; Maj M
    Biol Psychiatry; 1982 Jun; 17(6):711-7. PubMed ID: 7104421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder.
    Markota M; Coombes BJ; Larrabee BR; McElroy SL; Bond DJ; Veldic M; Colby CL; Chauhan M; Cuellar-Barboza AB; Fuentes M; Kung S; Prieto ML; Rummans TA; Bobo WV; Frye MA; Biernacka JM
    Transl Psychiatry; 2018 Sep; 8(1):188. PubMed ID: 30201969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
    Pearlson GD; Wong DF; Tune LE; Ross CA; Chase GA; Links JM; Dannals RF; Wilson AA; Ravert HT; Wagner HN
    Arch Gen Psychiatry; 1995 Jun; 52(6):471-7. PubMed ID: 7771917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasympathetic suppression of manic symptoms by physostigmine.
    Janowsky DS; el-Yousef K; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Apr; 28(4):542-7. PubMed ID: 4692153
    [No Abstract]   [Full Text] [Related]  

  • 9. [Catecholamine storage in schizophrenia].
    Baru AM; Mys'ko GN
    Vopr Med Khim; 1977; 23(4):550-4. PubMed ID: 919379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of aminazine on the excretion of adrenaline noradrenaline, dopamine and dopa in healthy subjects and in the manic phase of manic-depressive psychosis].
    Matlina ESh; Osipova MS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(1):128-31. PubMed ID: 5448719
    [No Abstract]   [Full Text] [Related]  

  • 11. Does dopamine have a role in schizophrenia?
    Carlsson A
    Biol Psychiatry; 1978 Feb; 13(1):3-21. PubMed ID: 341997
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis.
    Goodwin FK; Post RM
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():299-332. PubMed ID: 769117
    [No Abstract]   [Full Text] [Related]  

  • 13. The metabolism of norepinephrine in depressions. Differences and effects of therapies.
    Rosenblatt S; Chanley JD
    Can Psychiatr Assoc J; 1966; 11 Suppl():Suppl:50-60. PubMed ID: 5937839
    [No Abstract]   [Full Text] [Related]  

  • 14. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.
    Janowsky DS; el-Yousel MK; Davis JM; Sekerke HJ
    Arch Gen Psychiatry; 1973 Feb; 28(2):185-91. PubMed ID: 4630714
    [No Abstract]   [Full Text] [Related]  

  • 15. Obsessive-compulsive disorder in adolescence. Differential diagnostic considerations in relation to schizophrenia and manic-depressive disorder: a comparison of phenomenology and sociodemographic characteristics.
    Thomsen PH
    Psychopathology; 1992; 25(6):301-10. PubMed ID: 1293631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate metabolism in brain disease. III. Fructose metabolism in schizophrenic, manic-depressive, and involutional psychoses.
    HENNEMAN DH; ALTSCHULE MD; GONCZ RM
    AMA Arch Neurol Psychiatry; 1954 Dec; 72(6):696-704. PubMed ID: 13206488
    [No Abstract]   [Full Text] [Related]  

  • 17. The biochemistry of psychosis.
    Antun F
    J Med Liban; 1973; 26(6):615-25. PubMed ID: 4593351
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of psychoendocrine research on the sympathetic-adrenal medullary system.
    Mason JW
    Psychosom Med; 1968; 30(5):Suppl:631-53. PubMed ID: 4974233
    [No Abstract]   [Full Text] [Related]  

  • 19. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study.
    Guidotti A; Auta J; Davis JM; Di-Giorgi-Gerevini V; Dwivedi Y; Grayson DR; Impagnatiello F; Pandey G; Pesold C; Sharma R; Uzunov D; Costa E
    Arch Gen Psychiatry; 2000 Nov; 57(11):1061-9. PubMed ID: 11074872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological soft signs in manic patients. A comparison with Schizophrenic and control groups.
    Nasrallah HA; Tippin J; McCalley-Whitters M
    J Affect Disord; 1983 Feb; 5(1):45-50. PubMed ID: 6220043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.